AbbVie Inc. operates as a single global business segment dedicated to the research, development, and sale of pharmaceutical and biologic products. Its portfolio is concentrated in immunology (featuring treatments like Skyrizi, Rinvoq, and Humira), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Qulipta), and aesthetics (Botox Cosmetic, Juvederm). The company sells products in over 175 countries, with the United States accounting for the majority of its revenue. Formed as a spin-off from Abbott Laboratories, AbbVie has expanded its pipeline through internal research and strategic acquisitions, including Pharmacyclics, Allergan, and ImmunoGen. The company's principal business relies heavily on protein-based therapeutics and targeted immunomodulators.
